Olga A. Shavlovskaya
Olga A. Shavlovskaya has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Irina Anatolievna Bokova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
20 shared publications - Nikita I. Shavlovskiy
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
9 shared publications - Olga A. Gromova
Federal Research Center “Informatics and Control” of the Russian Academy of Sciences
9 shared publications - Igor D. Romanov
“MD-Clinic” medical centers
7 shared publications - I. D. Romanov
International University of Restorative Medicine
6 shared publications - Ivan Yu. Torshin
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
6 shared publications
Latest Publications
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 108-113
Potential strategies for managing chronic nonspecific lower back pain with the fixed-dose combination Dorsumio
Lower back pain (LBP) is discomfort localized between the twelfth pair of ribs and the gluteal folds. Chronic LBP, defined as pain persisting for 12 weeks or longer, is a significant global health concern, with a worldwide prevalence of 7.5% in 2017. In a Russian epidemiological study, the lower back was the most frequent site of chronic pain, accounting for 37% of cases. Among pharmacological interventions for LBP, nonsteroidal anti-inflammatory drugs (NSAIDs) and centrally acting muscle relaxants are most commonly used to reduce muscle tension and pain. Of note, 46% of patients with LBP experience depression of varying severity. For patients with chronic LBP, combination therapies incorporating both a muscle relaxant and an antidepressant, such as Dorsumio (comprising 6 mg of tizanidine and 15 mg of mirtazapine), are recommended. Several studies have demonstrated the efficacy and safety of Dorsumio in chronic LBP. The Board of Experts considers Dorsumio a rational option for patients with chronic LBP accompanied by mild to moderate depression.
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 108-113
Potential strategies for managing chronic nonspecific lower back pain with the fixed-dose combination Dorsumio
Lower back pain (LBP) is discomfort localized between the twelfth pair of ribs and the gluteal folds. Chronic LBP, defined as pain persisting for 12 weeks or longer, is a significant global health concern, with a worldwide prevalence of 7.5% in 2017. In a Russian epidemiological study, the lower back was the most frequent site of chronic pain, accounting for 37% of cases. Among pharmacological interventions for LBP, nonsteroidal anti-inflammatory drugs (NSAIDs) and centrally acting muscle relaxants are most commonly used to reduce muscle tension and pain. Of note, 46% of patients with LBP experience depression of varying severity. For patients with chronic LBP, combination therapies incorporating both a muscle relaxant and an antidepressant, such as Dorsumio (comprising 6 mg of tizanidine and 15 mg of mirtazapine), are recommended. Several studies have demonstrated the efficacy and safety of Dorsumio in chronic LBP. The Board of Experts considers Dorsumio a rational option for patients with chronic LBP accompanied by mild to moderate depression.
- Open Access
- 27 August 2026
- Published by Open Systems Publications in Лечащий врач
- No. 7-8(29),p. 82-88
Senolytics: a new perspective on connective tissue aging prevention and osteoarthritis therapy
Background. Aging processes affecting all organs and systems of the body, including connective tissue, supporting joints and spine, significantly reduce the quality of life of patients of elderly and senile age. Senescent cells are resistant to apoptosis, they have increased metabolic activity, without suppression of which the accumulation of senescent cells occurs, and leads to chronic inflammation and connective tissue dysfunction. Senescent cells have a powerful senescence-associated secretory phenotype, which can enhance the aging process by suppressing the function of stem cells, disrupting tissue homeostasis, and increasing aseptic inflammation. Senolytic drugs, which have the ability to suppress pro-inflammatory cytokines, transcription factors, growth factors, and kinases, can be used to delay the aging of connective tissue and the development of the age-dependent phenotype of osteoarthritis. Conclusion. One of the promising areas is the use of therapy that includes undenatured type II collagen in a standard dosage of 40 mg. Undenatured type II collagen can be considered as a potential geroprotector, as it has an immunomodulatory effect by inhibiting pro-inflammatory cytokines (tumor necrosis factor alpha, metalloproteinase-1 and -13, interleukin-1 and -6), increasing the synthesis of anti-inflammatory mediators (transforming growth factor beta, interleukin-4, interleukin-10), and thus reducing joint inflammation and promoting cartilage regeneration. Oral forms of undenatured type II collagen are used in the Russian market as part of the domestic Chondroguard TRIO. The experience of oral use of dietary supplements in patients with osteoarthritis and lower back pain with comorbid diseases is presented. The clinical efficacy and safety of auxiliary support with pharmaconutrient in patients of different age groups with different osteoarthritis phenotypes (post-traumatic, metabolic), in elderly patients with osteoarthritis of the knee joints are demonstrated.
- 27 August 2026
- Published by Open Systems Publications in Лечащий врач
- No. 7-8(29),p. 82-88
Open AccessSenolytics: a new perspective on connective tissue aging prevention and osteoarthritis therapy
Background. Aging processes affecting all organs and systems of the body, including connective tissue, supporting joints and spine, significantly reduce the quality of life of patients of elderly and senile age. Senescent cells are resistant to apoptosis, they have increased metabolic activity, without suppression of which the accumulation of senescent cells occurs, and leads to chronic inflammation and connective tissue dysfunction. Senescent cells have a powerful senescence-associated secretory phenotype, which can enhance the aging process by suppressing the function of stem cells, disrupting tissue homeostasis, and increasing aseptic inflammation. Senolytic drugs, which have the ability to suppress pro-inflammatory cytokines, transcription factors, growth factors, and kinases, can be used to delay the aging of connective tissue and the development of the age-dependent phenotype of osteoarthritis. Conclusion. One of the promising areas is the use of therapy that includes undenatured type II collagen in a standard dosage of 40 mg. Undenatured type II collagen can be considered as a potential geroprotector, as it has an immunomodulatory effect by inhibiting pro-inflammatory cytokines (tumor necrosis factor alpha, metalloproteinase-1 and -13, interleukin-1 and -6), increasing the synthesis of anti-inflammatory mediators (transforming growth factor beta, interleukin-4, interleukin-10), and thus reducing joint inflammation and promoting cartilage regeneration. Oral forms of undenatured type II collagen are used in the Russian market as part of the domestic Chondroguard TRIO. The experience of oral use of dietary supplements in patients with osteoarthritis and lower back pain with comorbid diseases is presented. The clinical efficacy and safety of auxiliary support with pharmaconutrient in patients of different age groups with different osteoarthritis phenotypes (post-traumatic, metabolic), in elderly patients with osteoarthritis of the knee joints are demonstrated.
- 28 July 2026
- Published by Medforum in Effective Pharmacotherapy
- Vol. 22 (23)
The Possibility Using Neipilept of Correcting Cognitive Disorders in Patients with Type 2 Diabetes Mellitus
One of the frequent neurological complications of type 2 diabetes mellitus (T2DM) is diabetic encephalopathy (DE), which is accompanied by cognitive impairment (CI). The pathogenetic mechanisms of DE include chronic hyperglycemia, recurrent hypoglycemic episodes, insulin resistance, as well as micro- and macroangiopathy. An analysis of the typical patient profile with T2DM shows that each of the risk factors (female sex – up to 70% of cases, elderly age over 65 years, presence of arterial hypertension (AH), changes in the vascular intima, lipid profile disorders, hyperglycemia, etc.) contributes to the development of CI and DE. The high comorbidity of T2DM and AH (up to 90%) leads to micro- and macroangiopathy, and the frequent and long-term coexistence of these pathological processes contributes to the progression of CI. The main causes of CI in the elderly are cerebrovascular diseases, against the background of which CI develops. Neuroprotective therapy with the domestic drug Neipilept (citicoline) may be recommended for patients with T2DM and CI for both therapeutic and prophylactic purposes to improve cognitive functions. The dosage regimen of Neipilept depends on the severity of CI and includes the following schedules: oral solution 500 mg per day for a course of 30 days; oral solution 1000 mg (10 ml) for two weeks, then 500 mg (5 ml) for another two weeks; tablets 500 mg twice daily for 30 days; tablets 500–1000 mg per day for three months; intramuscularly (IM) or intravenously (IV) 1000–2000 mg for a course of 10–14 days; subsequent courses are given at a six-month interval; sequential administration: first ten days – IV 1000 mg twice daily, then another ten days – IM 1000 mg per day.
- 28 July 2026
- Published by Medforum in Effective Pharmacotherapy
- Vol. 22 (23)
The Possibility Using Neipilept of Correcting Cognitive Disorders in Patients with Type 2 Diabetes Mellitus
One of the frequent neurological complications of type 2 diabetes mellitus (T2DM) is diabetic encephalopathy (DE), which is accompanied by cognitive impairment (CI). The pathogenetic mechanisms of DE include chronic hyperglycemia, recurrent hypoglycemic episodes, insulin resistance, as well as micro- and macroangiopathy. An analysis of the typical patient profile with T2DM shows that each of the risk factors (female sex – up to 70% of cases, elderly age over 65 years, presence of arterial hypertension (AH), changes in the vascular intima, lipid profile disorders, hyperglycemia, etc.) contributes to the development of CI and DE. The high comorbidity of T2DM and AH (up to 90%) leads to micro- and macroangiopathy, and the frequent and long-term coexistence of these pathological processes contributes to the progression of CI. The main causes of CI in the elderly are cerebrovascular diseases, against the background of which CI develops. Neuroprotective therapy with the domestic drug Neipilept (citicoline) may be recommended for patients with T2DM and CI for both therapeutic and prophylactic purposes to improve cognitive functions. The dosage regimen of Neipilept depends on the severity of CI and includes the following schedules: oral solution 500 mg per day for a course of 30 days; oral solution 1000 mg (10 ml) for two weeks, then 500 mg (5 ml) for another two weeks; tablets 500 mg twice daily for 30 days; tablets 500–1000 mg per day for three months; intramuscularly (IM) or intravenously (IV) 1000–2000 mg for a course of 10–14 days; subsequent courses are given at a six-month interval; sequential administration: first ten days – IV 1000 mg twice daily, then another ten days – IM 1000 mg per day.
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 48-55
Choline alfoscerate in the treatment of cognitive impairment
Multiple randomized controlled trials (RCTs), systematic reviews, meta-analyses, and multidisciplinary studies in both hospital and outpatient settings have demonstrated the high efficacy and safety of choline alfoscerate (CA) therapy for patients with mild and moderate cognitive impairment (MCI), amnestic cognitive impairment, predementia cognitive impairment in Alzheimer's disease (AD), elderly individuals, and first-degree relatives of patients with AD as preventive therapy. The Russian CA drug Cereton is available in several formulations, including solutions for intravenous and intramuscular injection, capsules, and an oral solution, enabling individualized treatment approaches. In hospital settings, injection therapy with Cereton is administered for 10 days, followed by an oral course lasting up to 60 days. The duration and dosage of Cereton oral solution and capsules are determined by patient age and clinical condition. The oral solution is approved for use in children from 6 years of age, and the capsules are approved for use in children from 11 years of age, with treatment courses lasting up to 60 days. Cereton therapy consists of two stages: initial intravenous or intramuscular administration, followed by oral administration of capsules or the oral solution. The drug is generally well-tolerated, with adverse events being infrequent and minor.
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 48-55
Choline alfoscerate in the treatment of cognitive impairment
Multiple randomized controlled trials (RCTs), systematic reviews, meta-analyses, and multidisciplinary studies in both hospital and outpatient settings have demonstrated the high efficacy and safety of choline alfoscerate (CA) therapy for patients with mild and moderate cognitive impairment (MCI), amnestic cognitive impairment, predementia cognitive impairment in Alzheimer's disease (AD), elderly individuals, and first-degree relatives of patients with AD as preventive therapy. The Russian CA drug Cereton is available in several formulations, including solutions for intravenous and intramuscular injection, capsules, and an oral solution, enabling individualized treatment approaches. In hospital settings, injection therapy with Cereton is administered for 10 days, followed by an oral course lasting up to 60 days. The duration and dosage of Cereton oral solution and capsules are determined by patient age and clinical condition. The oral solution is approved for use in children from 6 years of age, and the capsules are approved for use in children from 11 years of age, with treatment courses lasting up to 60 days. Cereton therapy consists of two stages: initial intravenous or intramuscular administration, followed by oral administration of capsules or the oral solution. The drug is generally well-tolerated, with adverse events being infrequent and minor.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 136-140
The effectiveness of citicoline in the treatment of cognitive disorders
Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4—12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3—9 months; 3) CI against the background of CCI at a dose of 500—2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson’s disease at a dose of 1000 mg/day 12—18 months.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 136-140
The effectiveness of citicoline in the treatment of cognitive disorders
Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4—12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3—9 months; 3) CI against the background of CCI at a dose of 500—2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson’s disease at a dose of 1000 mg/day 12—18 months.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 582-596
Therapeutic targets of disease-modifying therapy for secondary osteoarthritis (DMOADs): a systematic review
Secondary osteoarthritis (OA) may develop in the setting of various diseases and injuries of the joints, including rheumatoid arthritis (RA), psoriasis (psoriatic arthritis, PsA), and ankylosing spondylitis (AS). This article presents a systematic review of highly purified standardized drugs of chondroitin sulfate (CS) and glucosamine sulfate (GS) used in the treatment of secondary OA in various models of RA, PsA, and AS. The molecular links of targeting the pathogenesis of secondary OA are considered in specific detail. CS and GS are shown to inhibit hyperinflammation through the CD44 and TLR2/4/8 receptors, as well as the NF-κB transcription factor, thus acting as a disease-modifying therapy for RA, PsA, and AS. Experimental and clinical studies of the effects of CS and GS in RA, PsA, and AS have confirmed the prospects of their standardized forms for use in the treatment and prevention of the diseases under consideration.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 582-596
Therapeutic targets of disease-modifying therapy for secondary osteoarthritis (DMOADs): a systematic review
Secondary osteoarthritis (OA) may develop in the setting of various diseases and injuries of the joints, including rheumatoid arthritis (RA), psoriasis (psoriatic arthritis, PsA), and ankylosing spondylitis (AS). This article presents a systematic review of highly purified standardized drugs of chondroitin sulfate (CS) and glucosamine sulfate (GS) used in the treatment of secondary OA in various models of RA, PsA, and AS. The molecular links of targeting the pathogenesis of secondary OA are considered in specific detail. CS and GS are shown to inhibit hyperinflammation through the CD44 and TLR2/4/8 receptors, as well as the NF-κB transcription factor, thus acting as a disease-modifying therapy for RA, PsA, and AS. Experimental and clinical studies of the effects of CS and GS in RA, PsA, and AS have confirmed the prospects of their standardized forms for use in the treatment and prevention of the diseases under consideration.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 148-153
Ways to optimize the management of lower back pain patients at the outpatient stage
Objective. To assess the effectiveness of treating patients with lower back pain (LBP) by evaluating the impact on the severity of pain syndrome with the inclusion of chondroprotectors (CP) in parenteral and oral forms (intramuscularly (i.m.) administered Chondroguard, per oral (p/o) administered pharmaconutrient Chondroguard TRIO) in the treatment regimen. Material and methods. The treatment results are analyzed of 90 patients aged 18 to 45 (mean age 28.5±6.2 years) with a confirmed diagnosis of LBP. The patients were divided into three groups based on the prescribed treatment regimen. Group 1 patients (n=30; mean age 29.3±6.3 years) received meloxicam 7.5 mg 2 p/day for 10 days+tolperisone 150 mg 2 p/day for 10 days+B vitamin complex p/o 1 pills 1 p/day for 14 days (standard therapy, ST); Group 2 (n=30; mean age 30.2±6.5 years) ST+chondroitin sulfate (CS) preparation Chondroguard i.m. every other day, the first 3 injections (1st, 3rd, 5th days) — 1 ml (100 mg), with good tolerability from the 4th injection (day 7) — 2 ml (200 mg); Group 3 (n=30; mean age 29.7±5.7 years). ST+i.m. Chondroguard followed by per oral administration of the combined pharmaconutraceutical Chondroguard TRIO (1200 mg CS)+Glucosamine sulfate (GS, 1500 mg)+udenatured type II collagen (UC-II, 40 mg), 1 sachet/day for 2 months. Results. All treatment regimens for patients with LBP at the outpatient stage demonstrated positive dynamics of pain syndrome regression. On group 3, the best results were noted in terms of pain reduction from the initial level on the numerical rating scale (NRS) and prolongation of the effect (more than 2 months). When using Chondroguard TRIO, no adverse events were observed in any of the patients, and good tolerance of the drug and high patient adherence to the treatment were noted. Conclusion. In the treatment of patients with LBP, it is advisable to use chondroprotectors containing disease-modifying molecules, such as CS, GS, and UC-II, in addition to ST.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 148-153
Ways to optimize the management of lower back pain patients at the outpatient stage
Objective. To assess the effectiveness of treating patients with lower back pain (LBP) by evaluating the impact on the severity of pain syndrome with the inclusion of chondroprotectors (CP) in parenteral and oral forms (intramuscularly (i.m.) administered Chondroguard, per oral (p/o) administered pharmaconutrient Chondroguard TRIO) in the treatment regimen. Material and methods. The treatment results are analyzed of 90 patients aged 18 to 45 (mean age 28.5±6.2 years) with a confirmed diagnosis of LBP. The patients were divided into three groups based on the prescribed treatment regimen. Group 1 patients (n=30; mean age 29.3±6.3 years) received meloxicam 7.5 mg 2 p/day for 10 days+tolperisone 150 mg 2 p/day for 10 days+B vitamin complex p/o 1 pills 1 p/day for 14 days (standard therapy, ST); Group 2 (n=30; mean age 30.2±6.5 years) ST+chondroitin sulfate (CS) preparation Chondroguard i.m. every other day, the first 3 injections (1st, 3rd, 5th days) — 1 ml (100 mg), with good tolerability from the 4th injection (day 7) — 2 ml (200 mg); Group 3 (n=30; mean age 29.7±5.7 years). ST+i.m. Chondroguard followed by per oral administration of the combined pharmaconutraceutical Chondroguard TRIO (1200 mg CS)+Glucosamine sulfate (GS, 1500 mg)+udenatured type II collagen (UC-II, 40 mg), 1 sachet/day for 2 months. Results. All treatment regimens for patients with LBP at the outpatient stage demonstrated positive dynamics of pain syndrome regression. On group 3, the best results were noted in terms of pain reduction from the initial level on the numerical rating scale (NRS) and prolongation of the effect (more than 2 months). When using Chondroguard TRIO, no adverse events were observed in any of the patients, and good tolerance of the drug and high patient adherence to the treatment were noted. Conclusion. In the treatment of patients with LBP, it is advisable to use chondroprotectors containing disease-modifying molecules, such as CS, GS, and UC-II, in addition to ST.
- 9 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 140-144
The problem of digital overload: cognitive impairments in young people
The spread of new technologies and virtual communication using personal computers, tablets, and mobile phones has had a negative impact on people’s daily habits and behavior. The dependence on digital devices leads to the formation of a «psychological and emotional bond» between the user and their device, which can result in anxiety and depression, as well as cognitive impairment. Search queries on the Internet form and maintain in a person a doubt in previously acquired knowledge, requiring constant reference to a device (mobile phone, computer). In 2012, a new term «digital dementia» was introduced, which describes a possible decline in cognitive functions (in particular, memory) associated with excessive use of digital technologies (smartphones, computers, tablets). Emotional instability (apathy, irritability), which is caused by excessive use of gadgets, is accompanied by a decrease in concentration (due to constant switching between tasks), a deterioration in memory (the Internet replaces memorizing facts), and difficulties in analyzing complex information. Recognan (citicoline) is prescribed for the prevention and correction of emotional overload (anxiety, asthenia), as well as cognitive disorders that occur as a result of Internet addiction. The recommended dosage of Recognan is 500—1000 mg per day for 30 days. «Digital detox», which involves voluntarily reducing the use of digital devices, can have a positive impact on anxiety, asthenic symptoms, and cognitive impairments in Internet-addicted individuals.
- 9 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (11) , 140-144
The problem of digital overload: cognitive impairments in young people
The spread of new technologies and virtual communication using personal computers, tablets, and mobile phones has had a negative impact on people’s daily habits and behavior. The dependence on digital devices leads to the formation of a «psychological and emotional bond» between the user and their device, which can result in anxiety and depression, as well as cognitive impairment. Search queries on the Internet form and maintain in a person a doubt in previously acquired knowledge, requiring constant reference to a device (mobile phone, computer). In 2012, a new term «digital dementia» was introduced, which describes a possible decline in cognitive functions (in particular, memory) associated with excessive use of digital technologies (smartphones, computers, tablets). Emotional instability (apathy, irritability), which is caused by excessive use of gadgets, is accompanied by a decrease in concentration (due to constant switching between tasks), a deterioration in memory (the Internet replaces memorizing facts), and difficulties in analyzing complex information. Recognan (citicoline) is prescribed for the prevention and correction of emotional overload (anxiety, asthenia), as well as cognitive disorders that occur as a result of Internet addiction. The recommended dosage of Recognan is 500—1000 mg per day for 30 days. «Digital detox», which involves voluntarily reducing the use of digital devices, can have a positive impact on anxiety, asthenic symptoms, and cognitive impairments in Internet-addicted individuals.
- 16 October 2025
- Published by Bionika Media in Pharmateca
- Vol. 6_2025
Clinical application areas and regimens Recognan (citicoline) treatment in neurology
- 16 October 2025
- Published by Bionika Media in Pharmateca
- Vol. 6_2025
Clinical application areas and regimens Recognan (citicoline) treatment in neurology
- 5 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 41-45
Efficacy of Recognan in the therapy of neurological disorders after traumatic brain injury
Traumatic brain injury (TBI) is a brain injury caused by external mechanical stress, which leads to a deterioration in the patient’s health (temporary or irreversible), and is the main cause of death and disability. Along with neurodegenerative and cerebrovascular diseases, TBI is one of the main causes of cognitive impairment, as a result of injury. Among the neuroprotectors prescribed for the correction of neurological disorders after a TBI, the medicine drug (MD) Recognan (citicoline), which has neuroprotective and reparative effects, is of particular interest. The effectiveness of citicoline in TBI is assessed based on clinical studies and the results of neuroimaging methods: a decrease in cerebral edema, an increase in the percentage of patients who fully recovered 2 months after TBI, increasing the proportion of patients capable of self-care, improving cognitive functions. Recognan (citicoline) can be recommended for patients with TBI of varying severity according to the following regimens: 1) in the acutest period (1—7 days) with mild and moderate TBI — intravenously (i/v) drip at a dose of 500—1000 mg/day, with severe TBI — 2000 mg/day; 2) in the acute period (10—30 days) with mild and moderate TBI — per oral (p/o) at a dose of 1000 mg/day, with severe TBI — i/v 1000—2000 mg/day; 3) subacute and long–term period (1—3 months) with mild and moderate TBI — p/o at a dose of 500 mg/day, with moderate and severe TBI — p/o at a dose of 1000 mg/day.
- 5 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 41-45
Efficacy of Recognan in the therapy of neurological disorders after traumatic brain injury
Traumatic brain injury (TBI) is a brain injury caused by external mechanical stress, which leads to a deterioration in the patient’s health (temporary or irreversible), and is the main cause of death and disability. Along with neurodegenerative and cerebrovascular diseases, TBI is one of the main causes of cognitive impairment, as a result of injury. Among the neuroprotectors prescribed for the correction of neurological disorders after a TBI, the medicine drug (MD) Recognan (citicoline), which has neuroprotective and reparative effects, is of particular interest. The effectiveness of citicoline in TBI is assessed based on clinical studies and the results of neuroimaging methods: a decrease in cerebral edema, an increase in the percentage of patients who fully recovered 2 months after TBI, increasing the proportion of patients capable of self-care, improving cognitive functions. Recognan (citicoline) can be recommended for patients with TBI of varying severity according to the following regimens: 1) in the acutest period (1—7 days) with mild and moderate TBI — intravenously (i/v) drip at a dose of 500—1000 mg/day, with severe TBI — 2000 mg/day; 2) in the acute period (10—30 days) with mild and moderate TBI — per oral (p/o) at a dose of 1000 mg/day, with severe TBI — i/v 1000—2000 mg/day; 3) subacute and long–term period (1—3 months) with mild and moderate TBI — p/o at a dose of 500 mg/day, with moderate and severe TBI — p/o at a dose of 1000 mg/day.